What’s Ahead for Acasti Pharma Inc (ACST) After Today’s Significant Increase?

November 20, 2017 - By Stephen Andrade

The stock of Acasti Pharma Inc (NASDAQ:ACST) is a huge mover today! About 21.36M shares traded or 147628.06% up from the average. Acasti Pharma Inc (NASDAQ:ACST) has declined 3.13% since November 21, 2016 and is downtrending. It has underperformed by 19.83% the S&P500.
The move comes after 6 months positive chart setup for the $18.71M company. It was reported on Nov, 20 by Barchart.com. We have $3.18 PT which if reached, will make NASDAQ:ACST worth $1.12 million more.

More notable recent Acasti Pharma Inc (NASDAQ:ACST) news were published by: Marketwatch.com which released: “CORRECTION: Acasti Pharma Grants Stock Options” on June 16, 2017, also Quotes.Wsj.com with their article: “Acasti Pharma Inc.” published on January 08, 2013, Marketwired.com published: “Acasti Pharma Announces Development and Commercialization Discussions …” on November 20, 2017. More interesting news about Acasti Pharma Inc (NASDAQ:ACST) were released by: Marketwatch.com and their article: “1.63” published on November 28, 2016 as well as Marketwired.com‘s news article titled: “Acasti Pharma Reports First Quarter FY 2018 Financial Results” with publication date: August 14, 2017.

Acasti Pharma Inc is a Canada-based biopharmaceutical company. The company has market cap of $18.71 million. The Firm is focused on the research, development and commercialization of prescription drugs using omega 3 fatty acids derived from krill oil. It currently has negative earnings. OM3s has clinical evidence of safety and efficacy in lowering triglycerides in patients with hypertriglyceridemia (HTG).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.